Applied Therapeutics on partnership hunt as it seeks path forward after PhIII diabetic cardiomyopathy fail
Applied Therapeutics’ drug candidate for certain diabetic cardiomyopathy patients has disappointed in a late-stage study, although it showed potential in a prespecified subset. The company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.